JP2018506975A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506975A5 JP2018506975A5 JP2017542093A JP2017542093A JP2018506975A5 JP 2018506975 A5 JP2018506975 A5 JP 2018506975A5 JP 2017542093 A JP2017542093 A JP 2017542093A JP 2017542093 A JP2017542093 A JP 2017542093A JP 2018506975 A5 JP2018506975 A5 JP 2018506975A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- chimeric protein
- domain
- cell
- caspase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201503133A GB201503133D0 (en) | 2015-02-24 | 2015-02-24 | Chimeric protein |
| GB1503133.9 | 2015-02-24 | ||
| PCT/GB2016/050451 WO2016135470A1 (en) | 2015-02-24 | 2016-02-23 | Chimeric protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020038667A Division JP2020078359A (ja) | 2015-02-24 | 2020-03-06 | キメラタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506975A JP2018506975A (ja) | 2018-03-15 |
| JP2018506975A5 true JP2018506975A5 (enExample) | 2019-02-14 |
| JP6836508B2 JP6836508B2 (ja) | 2021-03-03 |
Family
ID=52822149
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542093A Active JP6836508B2 (ja) | 2015-02-24 | 2016-02-23 | キメラタンパク質 |
| JP2020038667A Withdrawn JP2020078359A (ja) | 2015-02-24 | 2020-03-06 | キメラタンパク質 |
| JP2022092922A Pending JP2022111273A (ja) | 2015-02-24 | 2022-06-08 | キメラタンパク質 |
| JP2024111258A Pending JP2024133176A (ja) | 2015-02-24 | 2024-07-10 | キメラタンパク質 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020038667A Withdrawn JP2020078359A (ja) | 2015-02-24 | 2020-03-06 | キメラタンパク質 |
| JP2022092922A Pending JP2022111273A (ja) | 2015-02-24 | 2022-06-08 | キメラタンパク質 |
| JP2024111258A Pending JP2024133176A (ja) | 2015-02-24 | 2024-07-10 | キメラタンパク質 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10098911B2 (enExample) |
| EP (2) | EP4147696A1 (enExample) |
| JP (4) | JP6836508B2 (enExample) |
| KR (2) | KR20230156817A (enExample) |
| CN (2) | CN116425882A (enExample) |
| AU (1) | AU2016225190B2 (enExample) |
| CA (1) | CA2973107C (enExample) |
| CL (1) | CL2017002134A1 (enExample) |
| DK (1) | DK3197453T3 (enExample) |
| ES (1) | ES2930623T3 (enExample) |
| GB (1) | GB201503133D0 (enExample) |
| HU (1) | HUE060267T2 (enExample) |
| IL (1) | IL252840B (enExample) |
| MX (1) | MX392658B (enExample) |
| PL (1) | PL3197453T3 (enExample) |
| PT (1) | PT3197453T (enExample) |
| RU (1) | RU2746755C2 (enExample) |
| SG (1) | SG11201705300VA (enExample) |
| WO (1) | WO2016135470A1 (enExample) |
| ZA (1) | ZA201704231B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201503133D0 (en) * | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| CA3007473A1 (en) * | 2015-12-14 | 2017-06-22 | Bellicum Pharmaceuticals, Inc. | Dual controls for therapeutic cell activation or elimination |
| DK3523325T3 (da) * | 2016-10-06 | 2025-11-10 | Poseida Therapeutics Inc | Inducerbare caspaser og fremgangsmåder til anvendelse |
| CN118546256A (zh) | 2016-12-13 | 2024-08-27 | 西雅图儿童医院（Dba西雅图儿童研究所） | 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法 |
| US11525146B2 (en) | 2017-01-09 | 2022-12-13 | Oisin Biotechnologies, Inc. | Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof |
| GB201709203D0 (en) | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| US20210130775A1 (en) * | 2017-08-02 | 2021-05-06 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| CN109593721B (zh) * | 2017-09-30 | 2022-11-01 | 亘喜生物科技（上海）有限公司 | 具有自杀基因开关的靶向人间皮素的工程化免疫细胞 |
| GB201716728D0 (en) | 2017-10-12 | 2017-11-29 | Autolus Ltd | Cell |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| CA3079096A1 (en) * | 2017-11-01 | 2019-05-09 | Allogene Therapeutics, Inc. | Modified caspase-9 polypeptides and methods of use thereof |
| EP3765491B1 (en) | 2018-03-14 | 2024-04-03 | Medigene Immunotherapies GmbH | Inducible t cell receptors and uses thereof |
| GB201805918D0 (en) | 2018-04-10 | 2018-05-23 | Autolus Ltd | Cell |
| EP3784252A4 (en) | 2018-04-18 | 2022-03-16 | Oisin Biotechnologies, Inc. | FUSOGENIC LIPID DNANOPARTICLES AND METHODS FOR THEIR PRODUCTION AND USE IN TARGET CELL SPECIFIC MANUFACTURE OF A THERAPEUTIC PROTEIN AND TREATMENT OF A TARGET CELL RELATED DISEASE, CONDITION OR DISORDER |
| CA3091490A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| GB201813178D0 (en) | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| CN113543792A (zh) | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
| GB201906126D0 (en) | 2019-05-01 | 2019-06-12 | Autolus Ltd | Chimeric protein |
| GB201913258D0 (en) | 2019-09-13 | 2019-10-30 | Autolus Ltd | Antigen-binding domain |
| GB201919019D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Antigen-binding domain |
| IT202000018064A1 (it) * | 2020-07-27 | 2022-01-27 | Univ Cattolica Del Sacro Cuore | Sviluppo di una nuova proteasi tobacco etch virus (tev) ingegnerizzata attivabile nel citosol o nel pathway secretorio |
| CN112575035B (zh) * | 2020-12-09 | 2022-11-29 | 贵州医科大学 | 一种诱导细胞凋亡的载体系统 |
| GB202019879D0 (en) | 2020-12-16 | 2021-01-27 | Ucl Business Ltd | Polypeptide |
| WO2022136874A1 (en) | 2020-12-23 | 2022-06-30 | Quell Therapeutics Limited | Inducible signalling protein |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| GB202209920D0 (en) | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
| WO2024251225A1 (en) * | 2023-06-07 | 2024-12-12 | Nanjing Legend Biotech Co., Ltd. | Rapamycin resistant cells and methods of use thereof |
| WO2024256824A1 (en) | 2023-06-14 | 2024-12-19 | Autolus Limited | Chimeric antigen receptors directed against trbc1 and trbc2 |
| GB202312009D0 (en) | 2023-08-04 | 2023-09-20 | Autolus Ltd | Methods and cell compositions |
| GB202403564D0 (en) | 2024-03-12 | 2024-04-24 | Autolus Ltd | Method |
| GB202405382D0 (en) | 2024-04-16 | 2024-05-29 | Ucl Business Ltd | Chimeric antigen receptor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU714904C (en) * | 1995-06-07 | 2002-08-08 | Ariad Pharmaceuticals, Inc. | Rapamcycin-based regulation of biological events |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| WO1996041865A1 (en) * | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| WO1999050425A2 (en) * | 1998-03-30 | 1999-10-07 | Baylor College Of Medicine | Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| US20040040047A1 (en) * | 1998-03-30 | 2004-02-26 | Spencer David M. | Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| US6916917B1 (en) | 1998-11-17 | 2005-07-12 | California Institute Of Technology | Chimeric pro-caspases and methods of using same |
| WO2003089627A1 (en) | 2002-04-19 | 2003-10-30 | Bioimage A/S | Translocation dependent complementation for drug screening |
| CA2593648A1 (en) * | 2005-01-10 | 2006-07-13 | Research Development Foundation | Targeted chimeric molecules for cancer therapy |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| KR101495651B1 (ko) * | 2012-09-03 | 2015-03-03 | 한국과학기술원 | 빛에 의해 이합체 형성을 유도하는 융합단백질 및 그의 용도 |
| SI3300745T1 (sl) | 2013-02-15 | 2020-01-31 | The Regents Of The University Of California | Himerni antigenski receptor in postopki njihove uporabe |
| CA2912172A1 (en) * | 2013-06-05 | 2014-12-11 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| CA2931684C (en) | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| US20150328292A1 (en) | 2014-03-07 | 2015-11-19 | Bellicum Pharmaceuticals, Inc. | Caspase polypeptides having modified activity and uses thereof |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| EP3234144B1 (en) * | 2014-12-15 | 2020-08-26 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| DK3234145T3 (da) | 2014-12-15 | 2019-08-19 | Bellicum Pharmaceuticals Inc | Fremgangsmåde til kontrollered aktivering eller eliminering af terapeutiske celler |
| GB201503133D0 (en) * | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| CN113543792A (zh) | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
-
2015
- 2015-02-24 GB GB201503133A patent/GB201503133D0/en not_active Ceased
-
2016
- 2016-02-23 US US15/526,097 patent/US10098911B2/en active Active
- 2016-02-23 KR KR1020237038544A patent/KR20230156817A/ko active Pending
- 2016-02-23 DK DK16707195.0T patent/DK3197453T3/da active
- 2016-02-23 EP EP22191585.3A patent/EP4147696A1/en active Pending
- 2016-02-23 AU AU2016225190A patent/AU2016225190B2/en active Active
- 2016-02-23 EP EP16707195.0A patent/EP3197453B9/en active Active
- 2016-02-23 ES ES16707195T patent/ES2930623T3/es active Active
- 2016-02-23 CN CN202211656921.4A patent/CN116425882A/zh active Pending
- 2016-02-23 SG SG11201705300VA patent/SG11201705300VA/en unknown
- 2016-02-23 CA CA2973107A patent/CA2973107C/en active Active
- 2016-02-23 CN CN201680006920.1A patent/CN107207621B/zh active Active
- 2016-02-23 RU RU2017132293A patent/RU2746755C2/ru active
- 2016-02-23 MX MX2017007848A patent/MX392658B/es unknown
- 2016-02-23 WO PCT/GB2016/050451 patent/WO2016135470A1/en not_active Ceased
- 2016-02-23 JP JP2017542093A patent/JP6836508B2/ja active Active
- 2016-02-23 PT PT167071950T patent/PT3197453T/pt unknown
- 2016-02-23 HU HUE16707195A patent/HUE060267T2/hu unknown
- 2016-02-23 KR KR1020177025985A patent/KR102601849B1/ko active Active
- 2016-02-23 PL PL16707195.0T patent/PL3197453T3/pl unknown
-
2017
- 2017-06-12 IL IL252840A patent/IL252840B/en active IP Right Grant
- 2017-06-21 ZA ZA2017/04231A patent/ZA201704231B/en unknown
- 2017-08-21 CL CL2017002134A patent/CL2017002134A1/es unknown
-
2018
- 2018-08-27 US US16/113,098 patent/US10478457B2/en active Active
-
2019
- 2019-10-10 US US16/598,652 patent/US11103532B2/en active Active
-
2020
- 2020-03-06 JP JP2020038667A patent/JP2020078359A/ja not_active Withdrawn
-
2022
- 2022-06-08 JP JP2022092922A patent/JP2022111273A/ja active Pending
-
2024
- 2024-07-10 JP JP2024111258A patent/JP2024133176A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017132293A (ru) | Химерный белок | |
| Willcox et al. | Butyrophilin-like 3 directly binds a human Vγ4+ T cell receptor using a modality distinct from clonally-restricted antigen | |
| Rice et al. | Recognition of the antigen-presenting molecule MR1 by a Vδ3+ γδ T cell receptor | |
| Li et al. | Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling | |
| Zeng et al. | γδ T cells recognize a microbial encoded B cell antigen to initiate a rapid antigen-specific interleukin-17 response | |
| EP3126380B1 (en) | Chimeric antigen receptor (car) signalling system | |
| EP3469362B1 (en) | Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof | |
| BR112021007626A2 (pt) | Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d) | |
| JP2016538855A5 (enExample) | ||
| BR112020007576A2 (pt) | composições e métodos para degradação de proteína seletiva | |
| JP2018517410A5 (enExample) | ||
| JP2015518479A5 (enExample) | ||
| JP2021533766A (ja) | 抗ｃｄ３３、抗ｃｌｌ１、ならびに少なくとも１つのさらなるｃａｒ抗ｃｄ１２３および／または抗ｆｔｌ３を含むｃａｒ ｔ細胞 | |
| SG194398A1 (en) | Cross-species-specific psmaxcd3 bispecific single chain antibody | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| JP2020530993A5 (enExample) | ||
| JP2019535292A5 (enExample) | ||
| Sharma et al. | Mucosal-associated invariant T cells develop an innate-like transcriptomic program in anti-mycobacterial responses | |
| Chao et al. | Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma | |
| JP2021531834A (ja) | Ａｆｐ抗原を識別するｔ細胞受容体 | |
| Füchsl et al. | Adoptive cellular therapy for multiple myeloma using CAR-and TCR-transgenic T cells: response and resistance | |
| Harley et al. | Enhancement of hERG channel activity by scFv antibody fragments targeted to the PAS domain | |
| JP2024535814A (ja) | キメラ抗原受容体（ｃａｒ）シグナル伝達分子の組成物及びその使用 | |
| Lee et al. | Identification of hnRNPH1, NF45, and C14orf166 as novel host interacting partners of the mature hepatitis C virus core protein | |
| Füchsl et al. | Paving the way to solid tumors: Challenges and strategies for adoptively transferred transgenic T cells in the tumor microenvironment |